All In Biotech

Drug Trial Radar · NCT00688688

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) 50 mg qd and 100 mg qd in Subjects With Symptoms of Overactive Bladder

Last checked: Nov 19, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,792 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,792

Actual

Start

Apr 25, 2008

Primary completion

May 6, 2010

Study completion May 6, 2010

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Jun 3, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active comparator.

Conditions

  • Urinary Bladder, Overactive

Interventions

  • MirabegronDrug

    Tablets

  • TolterodineDrug

    Extended release capsules

  • Placebo to MirabegronDrug

    Matching mirabegron placebo tablets.

  • Placebo to TolterodineDrug

    Matching tolterodine placebo capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With and Severity of Treatment-emergent Adverse Events (TEAEs)Time frame: From the first dose of double-blind study drug up until 30 days after the last dose of study drug, up to 13 months.

Locations

308 sites in 30 countries. Site status is shown where the registry gives one.

  • Site not named

    Homewood, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Montgomery, Alabama

  • Site not named

    Anchorage, Alaska

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Atherton, California

  • Site not named

    Beverly Hills, California

  • Site not named

    Buena Park, California

  • Site not named

    Fresno, California

  • Site not named

    La Mesa, California

  • Site not named

    Mission Hills, California

  • Site not named

    Newport Beach, California

  • Site not named

    Orange, California

  • Site not named

    Sacramento, California

  • Site not named

    San Bernardino, California

  • Site not named

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    Tarzana, California

  • Site not named

    Torrance, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Englewood, Colorado

  • Site not named

    New Britain, Connecticut

  • Site not named

    Waterbury, Connecticut

  • Site not named

    Aventura, Florida

  • Site not named

    Clearwater, Florida

  • Site not named

    Clearwater, Florida

  • Site not named

    Fort Myers, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Pembroke Pines, Florida

  • Site not named

    Pembroke Pines, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    Tallahassee, Florida

  • Site not named

    Tampa, Florida

Showing 40 of 308 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.